BERG Announces FDA Orphan-Drug Designation of BPM 31510 for the Treatment of Patients with Epidermolysis Bullosa NEWS PROVIDED BY BERG  May 23, 2018, 07:34 ET SHARE THIS ARTICLE BOSTON, May 23, 2018 /PRNewswire/ — BERG, LLC, a Boston-based biopharmaceutical company that merges biology with technology to map the nature of diseases, today announced that the U.S. Food and…

BERG Announces FDA Orphan-Drug Designation of BPM 31510 for the Treatment of Patients with Epidermolysis Bullosa NEWS PROVIDED BY BERG  May 23, 2018, 07:34 ET BOSTON, May 23, 2018 /PRNewswire/ — BERG, LLC, a Boston-based biopharmaceutical company that merges biology with technology to map the nature of diseases, today announced that the U.S. Food and Drug Administration (FDA)…

BERG, a biopharmaceutical company that merges biology with technology to map the nature of diseases, today announced the presentation of 10 abstracts describing progress on translational preclinical data on display at the American Association for Cancer Research (AACR) Annual Meeting in Chicago, being held from April 14-18. The data reinforce the clinical activity and potential…

BERG, a biopharmaceutical company that merges biology with technology to map the nature of diseases, today announced the dosing of the first patient in the United Kingdom (UK) for its Phase II pancreatic cancer clinical trial investigating the safety and efficacy of its drug candidate BPM 31510. This study builds upon early Phase II clinical…

BERG, a Boston-based biopharmaceutical company that merges biology with technology to map the nature of diseases, today announced the U.S. Food and Drug Administration (FDA) has granted orphan-drug designation to the Company’s leading product candidate BPM31510, for the treatment of pancreatic cancer. “The FDA’s orphan-drug designation marks an important milestone for BERG,” said Niven R….

BERG’s Interrogative Biology® Platform will Evaluate Clinically Annotated Biospecimens to Discover Diagnostic Biomarkers and Treatments for Neurological Diseases BOSTON — BERG, a biopharmaceutical company that merges biology with technology to map the nature of diseases, Massachusetts General Hospital (MGH), and Brigham and Women’s Hospital (BWH) today announced a research partnership to enhance the understanding of…